While first considered to be a potential cancer therapy agent due to its ability to inhibit PKC activity (O’Brian et al., 1985), tamoxifen later emerged as a drug candidate for mood stabilization given its PKC-inhibiting properties. This evidence concerns the gene PRRT2 and cancer.